Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
AssigneeKowa Company, Ltd.
InventorsYusuke Sasaki, Masato Asahiyama, Toshiya Tanaka
Life of this patent
Estimating the term…
Abstract
The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Claims16
A prophylactic and/or therapeutic agent for liver disease, comprising a combination of a PPARα agonist with an SGLT2 inhibitor.
A method for treating a subject suffering from or susceptible to a liver disease, the method comprising:
- administering to the subject a PPARα agonist and an SGLT2 inhibitor.
Dependencies are inferred from the claim text.